Key Question Answer

Global Market Outlook

In-depth analysis of global and regional trends

Analyze and identify the major players in the market, their market share, key developments, etc.

To understand the capability of the major players based on products offered, financials, and strategies.

Identify disrupting products, companies, and trends.

To identify opportunities in the market.

Analyze the regional penetration of players, products, and services in the market.

Comparison of major players financial performance.

Evaluate strategies adopted by major players.

Recommendations

Biologics Market
The biologics market is experiencing significant growth because these drugs have an impact on patient outcomes in cancer, autoimmune diseases, and many other diseases. Unlike traditional medicine, biologics are derived from biological materials including blood, protein, bacteria, and living organisms, including all types of sugars, proteins, DNA, and go to all cells and tissues. This unique resource, derived from various biological sources including humans, animals, and viruses, supports their effectiveness in preventing, treating, and curing many ailments. Therefore, the increasing demand and innovation in biologics is driving the expansion of the market and making biologics an important segment of the pharmaceutical industry.

Market Overview
The biologics industry is growing rapidly, driven by the unique and powerful nature of biopharmaceuticals produced using cells or organisms. These drugs, including gene therapy, tissue replacement, fusion proteins, antibiotics and monoclonal antibodies, are important in treating serious diseases and can be life-threatening. Biologics differ from traditional drugs in terms of ingredients, complex processes, manufacturing processes and regulatory requirements, and are often more expensive, which can limit patient access. Their ability to change the prevention, treatment and prognosis of many serious diseases underscores their business importance. Biologics include sugars, proteins, nucleic acids or complex combinations thereof, and even living things such as cells and tissues; they are derived from various natural sources such as humans, animals and organisms, and are produced using biotechnology, etc. advanced technology. This diversity and innovation are the main drivers of the burgeoning biologics industry.
For Instance
In May 2024, AGC Biologics and BioConnection joined forces to enable end-to-end drug and pharmaceutical product development and manufacturing. Episode

In June 2024, Lotte Biologics and Merck KGaA signed a collaboration agreement for the development of biopharmaceuticals. Episode

In October 2023, Samsung Biologics and Kurma Partners announced a partnership to develop and manufacture biologics for Kurma's leading companies. Article

Regional Insight
Biologics are marketed in North America, particularly the United States; biologics account for 38% to 40% of all drug use, while less than 2% of the U.S. population uses them. The distribution of biologics and new drug entities (NCEs) in 2023 is in line with recent trends, with 17 biologics compared to an average of 14 in the previous five years, and 38 NCEs compared to an average of 36. Biological drugs will account for 30% of all new drug approvals by 2023; this rate was about 28% in the previous five years, when 69 drugs out of a total of 247 were approved. The best performance in North America is seen primarily in biologics, driven by significant investment and innovation.

Asia Pacific is expected to witness the fastest growth of the biologics market during the forecast period. The Asia-Pacific task force emphasized that early use of biologic drugs can significantly improve clinical outcomes. Biological drugs such as etanercept, infliximab and more recently itolizumab and secukinumab have been used to treat psoriasis in India. Biosimilars have been on the market for many years and are expected to play an important role in the treatment of psoriasis in the future. Drugs approved for the treatment of psoriasis in China include tumor necrosis factor alpha (TNFα) inhibitors (etanercept, infliximab, adalimumab), the interleukin 12/23 inhibitor Utec monoclonal antibody, and the interleukin 17A inhibitor secukinumab. The adoption and widespread use of biological drugs demonstrates the potential for rapid economic growth and biotherapeutic innovation in the region.

By Segmentation
By Source
The microbial segment leads the biological industry, which is supported by the diversity and growth of secondary metabolites, or natural products produced by organisms such as bacteria, fungi, and plants. These natural products form the basis of many drugs with diverse chemical and biological activities, including antibiotics, antivirals, antivirals, and disease vaccines. Many treatments with important clinical applications for human diseases have been developed using these bioactive substances. The widespread use of microbial sources reflects their important role in driving the biologics industry and driving innovation in medicine.

The mammalian segment is expected to grow the fastest in the biologics market in the coming years. This expansion is driven by the growth of biopharmaceuticals, which are important in the treatment of many diseases such as oncology and rheumatology. Cultured mammalian cells have become an important guide for biopharmaceutical production because they can achieve the necessary post-transplantation stage that ensures the safety and efficacy of the drug. Over the past decade, advances in mammalian cell culture methods have increased, particularly in terms of numbers and production, reinforcing the important role and rapid growth of this field in the biological industry.

By Product
The monoclonal antibody (mAb) sector dominates the biological market due to its ability to target diseases with high precision. mAbs, derived from a single cell line, are immunoglobulins with specific properties designed to bind to a specific ligand or antigen. This binding purpose supports immune functions and, together with other functions, improves outcomes. Monoclonal antibodies are designed to treat many diseases and represent the cornerstone of biotherapeutics, highlighting their important role in supporting therapeutic targets and facilitating business growth and innovation.

The vaccines segment is expected to grow at the fastest pace in the coming years due to the urgent need to combat infectious diseases. The development of biological vaccines has led to significant advances in global and local health, as well as applications in the prevention and treatment of chronic diseases. Uncertainty about vaccination targets hinders the ability of health systems to make risky products viable. These challenges and the rapid growth of this segment highlight the important role this segment plays in improving public health outcomes and driving innovation in the biologics industry.

By Disease
The oncology segment dominates the market for biologics, which include drugs, vaccines, and antitoxins synthesized from living organisms or their derivatives and used as diagnostic, prophylactic, or therapeutic agents. These biologics can target cancer and work synergistically with chemotherapy for more effective treatment. Biologics that can be administered prior to the immune response by exploiting the immune system will be particularly effective. Although their high cost may prevent their widespread use, the efficacy and interest of biologics in oncology suggest that they play an important role in cancer treatment and improving patient outcomes.

The cardiovascular diseases (CVD) field is expected to grow the fastest in the coming years due to the recognition of the link between atherosclerosis, CVD, and inflammatory processes. Disease-modifying antiretroviral drugs (bDMARDs) have been shown to be beneficial in patients with autoimmune rheumatic diseases (ARDs), particularly rheumatoid arthritis (RA). In general, biologics can alter the lipid profile of patients with RA without affecting the TC/HDL ratio. The ability to improve cardiovascular outcomes through targeted therapies has led to a rapid increase in cardiovascular disease and has highlighted the important role of biologics in the treatment of heart disease.

Market Dynamics
Driver
Biologic therapies have become the drug of choice for the treatment of serious autoimmune diseases and, increasingly, osteoporosis. Biologics are defined as substances derived from living organisms that have been proven in clinical trials (RCTs) and clinical centers to prevent, diagnose, or treat a variety of diseases, including cancer and diseases. Studies show that they can slow the progression of pain by reducing pain, swelling, joint damage, skin and gastrointestinal conditions. Biologics can help improve the quality of life of people with arthritis, skin diseases and gastrointestinal disorders. This strong clinical activity has been a major driver of the growth of the biologics industry, underscoring their critical role in improving clinical outcomes and developing new therapeutics.

Restraints
Biologics derived from living organisms play an important role in treating complex diseases such as cancer, autoimmune diseases and diabetes, but their high cost remains a concern. There are many reasons for these numbers, including the complexity of biologic drugs, the extensive development process and long clinical trials that average ten years, and the large financial investment (up to $2.6 billion) required to bring a drug to market. Factors such as competition and market demand further impact price. Understanding and communicating these costs is critical for medical consultants (MSLs) and healthcare providers (HCPs) to explore the complexities of biotherapeutics and their impact on patient access and business growth.

Opportunity
Recent advances in manufacturing technology have opened new avenues for commercial biologics by increasing the potency and efficacy of these complex therapies. Innovations such as complex microparticles, nanoparticles, hydrogels, and 3D printing technology are enabling biologics to withstand severe physicochemical conditions while maintaining or even improving clinical outcomes. Combination strategies have emerged as a promising strategy with the potential to improve clinical outcomes, improve patient compliance, and target drug delivery. By jointly targeting multiple pharmacologically active sites, these advances aim to better reduce disease symptoms. This evolving landscape presents significant opportunities for biologics manufacturers to expand their businesses, develop new therapies, and ultimately improve patient outcomes through improved patient outcomes.

Recent developments
In May 2022, Viatris and Biocon Biologics launched a third oncology biosimilar, Abevmy (bevacizumab), in Canada. Article

In March 2024, Lonza signed an agreement to acquire a large biologics facility in Vacaville, VA, from Roche. Episode

In April 2022, Samsung Biological Products Company completed the acquisition of Samsung Bioepis. Episode

Choose License Type

Single User

$3999
Multi User

$5550
Enterprise User

$6999

Request Sample Ask For Customization Check Discount Speak TO Analyst Inquiry Before Buying

Our Reports Look Like This

HAVE A QUESTION

will help you find what you are looking for:

+91 7821962914

Biologics Market

Report ID : 625

Category : Pharmaceuticals

No Of Pages : No. of pages:

Published on: August 2024

Status: Published

Format :

Choose License Type

Our Reports Look Like This

HAVE A QUESTION

Related Reports

Published on July 2025

$ 3999

Published on June 2025

$ 3999

Published on June 2025

$ 3999

Published on June 2025

$ 3999

Published on June 2025

$ 3999

Published on June 2025

$ 3999

Recent Reports

Published on August 2024

$ 3999

Published on November 2024

$ 3999

Published on October 2024

$ 3999

Published on April 2024

$ 3999

Published on July 2024

$ 3999

Published on April 2024

$ 3999

Free Sample Request

Alternative Text

Subscribe to Newsletter